Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 28, 2003
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (dental, medical, and international) and Technology (practice management software).
Key Financial Metrics (Six Months Ended June 28, 2003)
| Metric | 2003 (6 Months) | 2002 (6 Months) | Change |
|---|---|---|---|
| Net Sales | $1,514.2 million | $1,318.5 million | +14.8% |
| Gross Profit | $421.9 million | $370.8 million | +13.8% |
| Gross Margin | 27.9% | 28.1% | -0.2% |
| Operating Income | $98.2 million | $82.2 million | +19.5% |
| Net Income | $57.6 million | $47.8 million | +20.6% |
| Diluted EPS | $1.29 | $1.07 | +20.6% |
| Operating Cash Flow | $41.0 million | $13.4 million | +206.4% |
| Cash & Equivalents | $121.2 million | $200.7 million (Year End) | -39.6% |
| Total Debt (Current + Long-term) | $256.8 million | $247.9 million (Year End) | +3.6% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased $195.7 million, driven primarily by the Healthcare Distribution segment (+14.7%). Growth was led by the Medical business (+18.4%) and International business (+27.4%), the latter boosted by favorable exchange rates and the acquisition of Hager Dental GmbH.
- Acquisitions: The company acquired Hager Dental GmbH (Germany) and Colonial Surgical Supply, Inc. (USA) in the second quarter. These transactions added approximately $31.3 million in goodwill and $13.5 million in other intangibles.
- Margin Compression: Overall gross margin decreased slightly to 27.9% from 28.1%, primarily due to sales mix changes in the medical business. However, the Technology segment saw margin expansion to 77.4%.
- Share Repurchases: The company repurchased 1,071,500 shares of common stock for $46.2 million during the period, reducing cash reserves significantly.
- Working Capital: Accounts receivable increased by $34.3 million due to higher sales volume, though the days sales outstanding ratio improved to 46.9 days from 50.0 days.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects to invest more than $35.0 million in capital projects for the fiscal year ending December 27, 2003, focusing on facility modernization and IT infrastructure.
- Liquidity: The company maintains a $200 million revolving credit facility (unutilized) and $121.2 million in cash. Management believes current resources are sufficient for foreseeable needs.
- Seasonality: Results are subject to seasonal fluctuations, with Q4 typically being the strongest due to year-end promotions and purchasing patterns.
- Key Risks:
- Competition: Intense competition from manufacturers selling directly to end-users and consolidation among distributors.
- Regulatory: Risks associated with government cost-cutting efforts (Medicare/Medicaid) and product liability claims (specifically 46 pending cases involving latex gloves).
- Legal Proceedings: A class action lawsuit regarding practice management software (Stromboe v. Henry Schein) was decertified by the Texas Supreme Court, though plaintiffs may attempt to recertify.
Investor Verification Checklist
- Acquisition Integration: Verify the financial performance and integration progress of Hager Dental GmbH and Colonial Surgical Supply.
- Working Capital Trends: Monitor the continued improvement in days sales outstanding (DSO) and inventory turns amidst sales growth.
- Legal Exposure: Track the status of the 46 product liability cases (latex gloves) and the potential for recertification of the software class action lawsuit.
- Debt Covenants: Review the terms of the $130 million and $100 million Senior Notes and the $200 million revolving credit facility.
- Stock-Based Compensation: Note that reported EPS excludes stock-based compensation expense under FAS 123; pro forma diluted EPS would be $1.16 for the six-month period.